Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Accured Expenses: 2020-2025

Historic Change in Accured Expenses for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $5.6 million.

  • Arcutis Biotherapeutics' Change in Accured Expenses fell 44.94% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.8 million, marking a year-over-year increase of 60.60%. This contributed to the annual value of $32.0 million for FY2024, which is 472.63% up from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Change in Accured Expenses stood at $5.6 million for Q3 2025, which was down 73.75% from $21.2 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Change in Accured Expenses registered a high of $21.2 million during Q2 2025, and its lowest value of -$5.5 million during Q1 2022.
  • Over the past 3 years, Arcutis Biotherapeutics' median Change in Accured Expenses value was $5.9 million (recorded in 2023), while the average stood at $5.8 million.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Change in Accured Expenses surged by 1,711.17% in 2021, and later slumped by 234.77% in 2023.
  • Over the past 5 years, Arcutis Biotherapeutics' Change in Accured Expenses (Quarterly) stood at $11.7 million in 2021, then slumped by 94.73% to $616,000 in 2022, then skyrocketed by 860.55% to $5.9 million in 2023, then skyrocketed by 122.80% to $13.2 million in 2024, then plummeted by 44.94% to $5.6 million in 2025.
  • Its last three reported values are $5.6 million in Q3 2025, $21.2 million for Q2 2025, and -$214,000 during Q1 2025.